Joey Med
Joey Med lists NAD injections and MOTS-C/tesamorelin products alongside generically named GLP-1 plans. The responsible clinician, actual preparation and supporting evidence need confirmation.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
Identify the actual prescription and practitioner before considering the broad recovery or metabolic claims. Testimonials and a generic GLP-1 plan name do not establish formulation-specific clinical evidence.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
MD Telehealth Platform LLC operates Joey Med. The current wellness menu explicitly names NAD injection, while its peptide menu offers a MOTS-C/tesamorelin combination alongside MOTS-C alone. Separate weight plans use GLP-1 Core and Plus labels without clearly assigning a current named ingredient to each.
What Joey Med prescribes, by goal
Longevity
- NAD+Compounding conditions apply
Listed by the seller; no price we hold.
NAD is explicitly offered by injection, but its precise preparation, concentration and regimen still require confirmation. Its role in cellular biology does not establish that an administered product improves energy or aging outcomes.
Who prescribes
A licensed clinician
The public treatment description names no individual prescriber responsible for every patient and does not identify a separate clinical group. It describes licensed professional review. A specific dispensing pharmacy is also not established. Request the actual practitioner, professional role, state authority and pharmacy before treatment.
Patients submit a health assessment for medical review, with more information requested when needed. Product pages describe provider oversight and support, while the consent permits telehealth evaluation. A guaranteed appointment format, regular reassessment schedule and patient-testing plan are not established by the product cards.
Are labs required?
Testing requirements and outside costs remain unconfirmed
The public product and prescribing descriptions do not establish a universal laboratory requirement, included allowance or repeat-testing charge.
Ready to start with Joey Med?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
The peptide marketing uses confident language about fat loss, recovery and energy. Its general results disclaimer does not supply the missing preparation-specific evidence. Ask which outcomes have been studied, which remain uncertain and what monitoring or alternatives the clinician recommends. Customer reviews span different services. Their inclusion beside a peptide card does not show that every reviewer used that product or experienced a clinically measured benefit.
Other products and treatment claims
- MOTS-c
- On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- Tesamorelin
- Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
How it bills
The NAD page shows $300 against a $350 comparison and offers monthly and three-month supply choices, without clearly allocating the selected figure. MOTS-C starts at $199 and the combination at $299, with purchase duration and exact administration details unresolved. Refund terms distinguish prescribing and shipment stages. Conditional deductions after shipment are not routine fees automatically added to every treatment. Obtain the selected product, clinical charges, testing and cancellation terms together.
For and against
- For: Named current peptide products
- For: Telehealth consent public
- For: Refund stages described
- Against: Actual prescriber and pharmacy unidentified
- Against: Confident benefit claims need stronger evidence
- Against: Product quantity and price allocation incomplete
The evidence behind what it sells
Right for
Someone willing to verify the actual peptide formulation, responsible clinician and human evidence before considering the menu.
Look elsewhere if
Someone treating a generic class name, customer testimonial or natural biological role as proof of a specific prescription’s benefit.
Other sellers for longevity
LumiMeds
Also prescribes NAD+.
Fresh Day Meds
Also prescribes NAD+.
Fierce Health
Also prescribes NAD+.
Joey Med
Frequently asked questions
- Does the GLP-1 Core name identify semaglutide?
- The current named plan does not establish that ingredient mapping by itself.
- Do customer reviews prove the peptide worked?
- They do not establish the product used, measured outcome or preparation-specific evidence.
- Is the exact NAD preparation identified?
- The injection route is named, but formulation, concentration and supply classification need confirmation.
Sources
- Current NAD route, card and supply choices
- MOTS-C and combination current offers
- MOTS-C benefit claims and starting figure
- Combination claims and starting figure
- Stage-specific refunds and conditional deductions
- Operator and platform roles
- Medical review and consent
- Current generic GLP-1 plan description
See what Joey Med prescribes today
Joey Med sets its own prices, plans and the states it serves. Check them before you start.